Indonesia Ends Antidumping Investigation on Chinese Synthetic Yarn No Duties Imposed
On June 16, 2025, the Indonesian Anti-Dumping Committee (KADI) announced in notice AD.02/253/KADI/06/2025 the decision to terminate the antidumping investigation on synthetic filament yarn originating from China. KADI stated that imposing antidumping duties would not align with national interests, given the domestic supply shortage in Indonesia’s textile industry.
The investigation, initiated on September 12, 2023, targeted Chinese synthetic filament yarn under the tariff codes 5402.33.10, 5402.33.90, 5402.46.10, and 5402.46.90. A final affirmative determination was issued on March 11, 2025, recommending a five-year antidumping duty on the products. However, the Indonesian government has now decided against implementing the measure.
This decision reflects KADI's consideration of domestic industry needs and its efforts to balance import reliance with local production capacity. The termination is expected to support the stability of Indonesia’s textile sector.
2026-10-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
BASF India to Shut Two Dahej Care Chemicals Plants as Overcapacity Squeezes Margins
-
LANXESS Specialty Additives Earnings Jump 32.8%, but Chemical Demand Recovery Remains Elusive
-
BASF Brings Biomass-Balance Polyols to North America
-
Production Down 6%, Profits Cut by $3.7 Billion: Middle East Conflict Hits ExxonMobil Hard
-
Wanhua Chemical's Hungarian 650,000-ton MDI/TDI Plant to Shut Down for 35-Day Maintenance
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
DyStar Becomes a Wholly-Owned Subsidiary of Zhejiang Longsheng Group, Ending Longstanding Shareholder Disputes with a $5 Billion Deal
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
Recommend Reading
-
Ingredion Agrees to Acquire Tate & Lyle for $3.6 Billion, Reshaping the Global Specialty Ingredients Market
-
Wanhua Chemical and Xingfa Group Jointly Develop 5.32 Billion Yuan Phosphate Mine
-
AstraZeneca Pays Up to $1.5 Billion for Global Rights to Chinese Lung Cancer Drug
-
Novo Nordisk’s Oral Wegovy Wins EU Approval as Weight-Loss Competition Shifts from Injections to Pills
-
Hormuz Crisis Pushes Up Urea Prices as Yara’s Quarterly EBITDA Jumps 39%
-
2025 Review of Acrylonitrile Industry Events in China
-
Business Society’s Diesel Trend Analysis for September 17, 2026: Volatile Performance
-
Following Cost Fluctuations, PTA Prices in China Rose First and Then Declined in September
-
September Styrene Market Fluctuates and Rises in China
-
China's SBR Prices Rise Driven by Costs